Last reviewed · How we verify

NCT04528303

Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty

Recruiting now NA Last updated 24 March 2026
What this trial tests

NA trial testing Whole genome sequencing in Diarrhea, Infantile in 180 participants. Currently enrolling.

Timeline
1 May 2024
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorChildren's Hospital of Fudan University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposediagnostic
Enrollment180
Start date1 May 2024
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Fudan University

Who can join

Under 6, any sex, with Diarrhea, Infantile or Enteropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will seek to determine if whole genome sequencing (WGS) improves diagnostic rates, and outcomes for congenital diarrhea and enteropathy (CODE) patients. The investigator will enroll 180 patients in a randomized controlled study to either WGS or whole exome sequencing (WES). This study is designed to evaluate whether CODE patients would benefit from WGS guided precision medicine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Whole genome sequencing

Trials testing the same drug.

Other recruiting trials for Diarrhea, Infantile

Currently open trials in the same condition.

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04528303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing